Production (Stage)
Lotus Bio-Technology Development Corp.
LBTD
$0.00
$0.000.00%
OTC PK
| 12/31/2017 | 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -96.67% | 393.55% | -93.33% | -100.05% | 318.60% |
| Depreciation & Amortization | -- | -- | -- | -245.45% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -96.67% | 393.55% | -93.33% | -100.26% | 318.60% |
| Operating Income | 96.67% | -393.55% | 93.33% | 100.26% | -318.60% |
| Income Before Tax | 96.67% | -393.55% | 93.33% | 100.40% | -176.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.67% | -393.55% | 93.33% | 100.40% | -176.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.67% | -393.55% | 93.33% | 100.40% | -176.92% |
| EBIT | 96.67% | -393.55% | 93.33% | 100.26% | -318.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 100.00% | -- | -- | 100.00% | -- |
| Normalized Basic EPS | 100.00% | -- | -- | 100.00% | -- |
| EPS Diluted | 100.00% | -- | -- | 100.00% | -- |
| Normalized Diluted EPS | 100.00% | -- | -- | 100.00% | -- |
| Average Basic Shares Outstanding | 303.99% | 59.09% | 0.00% | -54.59% | -54.34% |
| Average Diluted Shares Outstanding | 303.99% | 59.09% | 0.00% | -54.59% | -54.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |